ReviewInflammatory bowel diseases2019
A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD.
Review in Inflammatory bowel diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 68 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Diseases.Inflammatory bowel diseases · 2026Pooled it
- The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis.Nutrients · 2019Pooled it
- Combined Probiotics and Antioxidants Attenuate LPS-Induced Acute Intestinal Inflammation via Multi-Pathway Regulation in a Preventive Mouse Model.Antioxidants (Basel, Switzerland) · 2026Article
- A novel inflammatory bowel disease registry powered by artificial intelligence and natural language processing.PLOS digital health · 2026Article
- From Conventional Therapy to Precision Medicine in Inflammatory Bowel Disease: A State-of-the-Art Review.Biomedicines · 2026Review
- Luteolin Inhibits NLRP3 Inflammasome Activation to Ameliorate DSS-Induced Colitis by Regulating AMPK Signalling.Cell proliferation · 2026Article
- ASSOCIATED FACTORS AND CLINICAL ASPECTS OF COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS - EXPERIENCE OF A BRAZILIAN SOUTHEASTERN COHORT.Arquivos de gastroenterologia · 2026Observational
- Macrophage-related GBP4 as a Novel Biomarker for Crohn's Disease: Insights from WGCNA, Mendelian Randomization, and Immunohistochemical Validation.Current topics in medicinal chemistry · 2026Article
- A narrative review of the ileal pouch in pediatric inflammatory bowel disease and familial adenomatous polyposis.Journal of pediatric gastroenterology and nutrition · 2025Review
- Risk Factors for Chronic Kidney Disease in Patients With Crohn's Disease.Inflammatory bowel diseases · 2025Article
- Identification of subtypes and biomarkers associated with disulfidptosis-related ferroptosis in ulcerative colitis.Hereditas · 2025Article
- Ameba-inspired strategy enhances probiotic efficacy via prebound nutrient supply.Nature communications · 2025Article
- Xianglian Anchang Decoction Mitigates Ulcerative Colitis via Inhibition of TLR-4-Mediated Pyroptosis.Journal of inflammation research · 2025Article
- Article
- Differential Diagnosis Value of Neutrophil Gelatinase Associated Lipocalin as a Noninvasive Biomarker in Perianal Fistulizing Crohn's Disease.Journal of inflammation research · 2025Article
- Comprehensive analysis of anoikis-related gene signature in ulcerative colitis using machine learning algorithms.Frontiers in medicine · 2025Article
- Exploring Dual-Targeted Therapy in the Management of Moderate to Severe Inflammatory Bowel Disease: A Retrospective Study.Crohn's & colitis 360 · 2025Article
- Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease.World journal of gastroenterology · 2024Observational
- Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease.Scientific reports · 2024Article
- Use of Complementary and Alternative Therapies in People with Inflammatory Bowel Disease.International journal of environmental research and public health · 2024Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Over the last 2 decades, novel therapies targeting several immune pathways have been developed for the treatment of patients with inflammatory bowel disease (IBD). Although anti-tumor necrosis factor (anti-TNF) agents remain the firstline treatment for moderate to severe Crohn's disease and ulcerative colitis, many patients will require alternative agents, due to nonresponse, loss of response, or intolerance of anti-TNFs. Furthermore, patients may request newer therapies due to improved safety profiles or improved administration (ie, less frequent injection, oral therapy). This review will focus on new and emerging therapies for the treatment of IBD, with a special focus on their adverse effects. Although many of the agents included in this paper have been approved for use in IBD, a few are still in development but have been shown to be effective in phase II clinical trials. 10.1093/ibd/izy327_video1 izy327.video1 5967364908001.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.